ActoBio Therapeutics™ receives IND green light for antigen-specific immunotherapy study
ActoBio announced the FDA has given its permission to an IND application for AG017, an innovative orally-delivered therapeutic candidate for treatment of celiac disease. ActoBio Therapeutics™ plans to enroll celiac disease patients in the Phase Ib/IIa study in the U.S. and Europe later this year. August 19, 2019